NEJM:可疑冠状动脉疾病的非侵入性检查比较(PROMISE试验)

2015-03-15 MedSci MedSci原创

Exception Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUs

很多病人都会有提示冠状动脉疾病(CAD)的症状,只有诊断试验(冠脉造影)才能确定是否有CAD,对于要求非侵入性检查的患者,目前临床上还缺乏相关随机对照试验数据去指导检查。

因此Pamela S等人进行了一项随机试验,该研究共纳入10,003名有可疑CAD症状的病人,按照解剖结构的检查(CTA)和心脏功能试验(心电图运动试验、核素心脏负荷试验、负荷超声心动图)分为两组。初始结局指标为死亡、心肌梗死、住院治疗不稳定心绞痛等,继发指标为侵入性心导管介入术(冠脉造影)提示没有阻塞性CAD和射线暴露量。

研究对象平均年龄为60.8±8.3岁,其中52.7%女性,87.7%的患者有胸痛或劳力性呼吸困难,对于阻塞性CAD预测为53.3±21.4%。在平均超过25个月的随访后发现,初始结局指标在CTA组为164/4996(3.3%),在心功试验组151/5007(3.0%)(aHR 1.04,95% CI 0.83-1.29,P=0.75)。在CTA组有更少的冠脉造影提示没有阻塞性CAD (3.4% vs. 4.3%,P = 0.02),但是CTA组在90天内冠脉造影人数更多(12.2% vs. 8.1%)。平均每个病人的累积射线暴露CTA组更低(10.0 mSv vs. 11.3 mSv),但是功能试验组有32.6%的患者射线零暴露,所以CTA组在整体上射线暴露更高(12.0 mSv vs. 10.1 mSv; P<0.001)。

在平均超过2年的随访结果表明,对于有症状怀疑冠状动脉疾病的患者,若要求非侵入性检查,那么CTA的使用,较之心脏功能试验,并不能改善临床结局。

原始出处:


Pamela S. Douglas, M.D., Udo Hoffmann, M.D., M.P.H., Manesh R. Patel, M.D., Daniel B. Mark, M.D., M.P.H., Hussein R. Al-Khalidi, Ph.D., Brendan Cavanaugh, M.D., Jason Cole, M.D., Rowena J. Dolor, M.D., Christopher B. Fordyce, M.D., Megan Huang, Ph.D., Muhammad Akram Khan, M.D., Andrzej S. Kosinski, Ph.D., Mitchell W. Krucoff, M.D., Vinay Malhotra, M.D., Michael H. Picard, M.D., James E. Udelson, M.D., Eric J. Velazquez, M.D., Eric Yow, M.S., Lawton S. Cooper, M.D., M.P.H., and Kerry L. Lee, Ph.D. for the PROMISE Investigators.Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease.NEJM March 14, 2015DOI: 10.1056/NEJMoa1415516

本文系Medsci原创编译整理!转载需要先获得授权,并附原文链接。谢谢!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2028739, encodeId=57b62028e391f, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Sep 27 03:10:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020082, encodeId=7600202008248, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sun May 03 07:10:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034661, encodeId=17092034661d0, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sun Apr 26 05:10:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252861, encodeId=7b33125286135, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Mar 17 14:10:00 CST 2015, time=2015-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601736, encodeId=b94f1601e3695, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Mar 17 14:10:00 CST 2015, time=2015-03-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2028739, encodeId=57b62028e391f, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Sep 27 03:10:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020082, encodeId=7600202008248, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sun May 03 07:10:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034661, encodeId=17092034661d0, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sun Apr 26 05:10:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252861, encodeId=7b33125286135, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Mar 17 14:10:00 CST 2015, time=2015-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601736, encodeId=b94f1601e3695, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Mar 17 14:10:00 CST 2015, time=2015-03-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2028739, encodeId=57b62028e391f, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Sep 27 03:10:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020082, encodeId=7600202008248, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sun May 03 07:10:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034661, encodeId=17092034661d0, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sun Apr 26 05:10:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252861, encodeId=7b33125286135, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Mar 17 14:10:00 CST 2015, time=2015-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601736, encodeId=b94f1601e3695, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Mar 17 14:10:00 CST 2015, time=2015-03-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2028739, encodeId=57b62028e391f, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Sep 27 03:10:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020082, encodeId=7600202008248, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sun May 03 07:10:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034661, encodeId=17092034661d0, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sun Apr 26 05:10:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252861, encodeId=7b33125286135, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Mar 17 14:10:00 CST 2015, time=2015-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601736, encodeId=b94f1601e3695, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Mar 17 14:10:00 CST 2015, time=2015-03-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2028739, encodeId=57b62028e391f, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Sep 27 03:10:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020082, encodeId=7600202008248, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sun May 03 07:10:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034661, encodeId=17092034661d0, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sun Apr 26 05:10:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252861, encodeId=7b33125286135, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Mar 17 14:10:00 CST 2015, time=2015-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601736, encodeId=b94f1601e3695, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Mar 17 14:10:00 CST 2015, time=2015-03-17, status=1, ipAttribution=)]
    2015-03-17 sunylz

相关资讯

CIT 2014:冠脉分叉病变RESOLVE评分

研究背景冠状动脉分叉病变始终是经皮冠状动脉介入治疗(PCI)中的一个难题,也是PCI中的常见病变,约占PCI总量的15%~20%。目前分叉病变介入治疗策略主要有选择性双支架技术和临时决定的双支架技术。选择性双支架技术如Crush等技术可有效保证分支血管通畅,但操作复杂且费用高;临时决定的双支架技术操作简单,但易使分支闭塞,进而导致患者心肌缺血、急性心肌梗死甚至死亡。分叉病变的介入治疗策略对术后即刻

JAMA:冠状动脉疾病患者局部心肌变薄与疤痕负荷有关

心血管CMR分析 局部左心室壁变薄被认为是透壁性心肌梗塞和瘢痕组织的表现。然而,最近的病例报道使用延迟增强心血管磁共振(CMR)成像技术揭示了室壁变薄可能存在于有限瘢痕负荷或无瘢痕负荷患者的可能性。 为了评估局部心肌壁变薄患者并明确瘢痕负荷和机能改善之间的关系,杜克大学心血管研究中心的Raymond J. Kim博士及其同事进行了深入研究,他们发现,CMR检查显示局部室壁变薄的CAD患者中

ESC 2013:稳定性冠状动脉疾病指南

2013年9月1日,由Gilles Montalescot及UdoSechtem领导的工作小组在欧洲心脏病学会年会(ESC2013)上公布了最新的稳定性冠状动脉疾病指南。【全文阅读】本次更新的主要内容为:1.自2006年稳定性心绞痛管理与治疗指南出台之后,稳定性冠状动脉疾病(SCAD)的概念已经发生了变革,其范围更加广泛,除以冠状动脉血栓形成为主要临床表现的急性冠脉综合征外,很多CAD均属于SCA

TCT 2014:美国稳定冠脉CTO PCI治疗较少

 TCT2014公布的一项研究表明,目前在美国稳定的冠状动脉疾病行慢性完全闭塞病变(CTO)经皮冠脉介入治疗(PCI)的治疗很少,与非CTO PCI相比较,它具有较低的成功率和更高的并发症发生率。CTO PCI手术的成功是与一些病人因素和术者操作经验相关的。 CTO PCI可以带来显著的临床益处,然而在非选择的病人群体中它的成功率及安全性信息是有限的,该研究试图描述目前在美国的

冠状动脉杂交技术(HCR)在冠状动脉血运重建中的应用争鸣

    随着愈来愈多合并多重高危因素的冠心病病人转诊至心脏外科,心脏外科医生面临着冠心病的手术风险愈来愈高。为了减少手术创伤,降低手术风险,冠状动脉搭桥技术不断改进,包括非体外循环下不停跳冠状动脉搭桥术(OPCAB)和微创小切口冠状动脉搭桥术(MIDCAB)。MIDCAB主要适用于心脏前壁的血管,尤其是左前降支(LAD),临床中远期疗效满意。虽然经皮冠状动脉介入治疗(